IVIG Privigen denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Privigen as Non-Formulary — and Why You Can Appeal

Privigen (immune globulin intravenous, 10%) may not appear on UnitedHealthcare's preferred formulary tier, or may require a formulary exception before the plan will cover it at the standard benefit level. A non-formulary denial does not mean Privigen is clinically inappropriate — it means the plan has designated a different IVIG product as its preferred option. However, formulary exceptions are available when a formulary alternative is medically inadequate for your specific situation, and these exceptions are a well-established part of the appeal process.

## Why This Denial Is Appealable

Formulary exceptions exist precisely because a one-size-fits-all formulary cannot account for every patient's clinical needs. If the preferred IVIG alternative is contraindicated, has caused adverse reactions in your history, or is otherwise clinically inferior for your specific condition, your prescriber can document that clinical distinction to support a formulary exception. UHC is required to evaluate formulary-exception requests on their individual clinical merits.

## Federal Appeal Framework

• ERISA §503 (employer plans): Requires UHC to disclose the formulary criteria and conduct a genuine review of your exception request.
• ACA §2719 / State external review: If internal levels are exhausted, an independent external reviewer can overturn a formulary denial when the clinical basis for the exception is sound. Act within approximately four months of your denial notice.
• Expedited review: Request it if your next scheduled infusion is imminent or if switching to a formulary alternative mid-treatment poses clinical risk.

## Your Appeal Process

1. Obtain the denial letter and UHC's current formulary, identifying the preferred IVIG alternative(s) listed. 2. Confirm with your prescriber whether the preferred alternative is appropriate for your case. 3. File a formulary exception request (often a prerequisite to a formal appeal) with clinical documentation. 4. If the exception is denied, file a formal Level 1 appeal and escalate as needed.

## Documentation to Gather

• Diagnosis and indication: Specialist notes confirming your FDA-recognized indication for Privigen.
• Formulary-alternative assessment: Your prescriber's documented review of why the preferred alternative is clinically inadequate — for example, prior adverse reaction, tolerability issue, indication mismatch, or infusion-site formulary constraint.
• Prior adverse-reaction or failure records: If you have previously received an alternative IVIG and experienced a reaction or inadequate response, include those clinical notes with dates.
• Infusion-center formulary documentation: If your infusion facility only stocks Privigen (or the alternative is unavailable at your provider), document this access barrier.
• Medical-necessity letter: Your prescriber's explanation of why Privigen specifically — rather than the preferred alternative — is medically necessary for your case.

## Criteria-Mapping Strategy

Request UHC's formulary-exception criteria and compare them against your documentation. Map each exception criterion to a specific chart fact. The clearest exception cases are those where the preferred alternative has already been tried and failed, or where a documented clinical reason precludes its use. A structured table makes the exception basis immediately legible to the reviewer.